Annual CFF
$69.60 M
+$15.27 M+28.12%
December 31, 2023
Summary
- As of February 7, 2025, CHRS annual cash flow from financing activities is $69.60 million, with the most recent change of +$15.27 million (+28.12%) on December 31, 2023.
- During the last 3 years, CHRS annual CFF has fallen by -$154.35 million (-68.92%).
- CHRS annual CFF is now -69.23% below its all-time high of $226.18 million, reached on December 31, 2016.
Performance
CHRS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$167.00 K
+$187.76 M+99.91%
September 30, 2024
Summary
- As of February 7, 2025, CHRS quarterly cash flow from financing activities is -$167.00 thousand, with the most recent change of +$187.76 million (+99.91%) on September 30, 2024.
- Over the past year, CHRS quarterly CFF has dropped by -$11.27 million (-101.50%).
- CHRS quarterly CFF is now -100.08% below its all-time high of $210.42 million, reached on June 30, 2020.
Performance
CHRS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$186.84 M
-$11.27 M-6.42%
September 30, 2024
Summary
- As of February 7, 2025, CHRS TTM cash flow from financing activities is -$186.84 million, with the most recent change of -$11.27 million (-6.42%) on September 30, 2024.
- Over the past year, CHRS TTM CFF has dropped by -$262.67 million (-346.40%).
- CHRS TTM CFF is now -173.01% below its all-time high of $255.89 million, reached on September 30, 2017.
Performance
CHRS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
CHRS Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +28.1% | -101.5% | -346.4% |
| 3 y3 years | -68.9% | -100.3% | -264.5% |
| 5 y5 years | -34.0% | -100.3% | -264.5% |
CHRS Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +34.2% | -100.3% | +99.9% | -264.5% | at low |
| 5 y | 5-year | -68.9% | +34.2% | -100.1% | +99.9% | -183.4% | at low |
| alltime | all time | -69.2% | +599.1% | -100.1% | +99.9% | -173.0% | at low |
Coherus BioSciences Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$167.00 K(-99.9%) | -$186.84 M(+6.4%) |
| Jun 2024 | - | -$187.93 M(<-9900.0%) | -$175.57 M(-363.3%) |
| Mar 2024 | - | $887.00 K(+142.3%) | $66.68 M(-4.2%) |
| Dec 2023 | $69.60 M(+28.1%) | $366.00 K(-96.7%) | $69.60 M(-8.2%) |
| Sep 2023 | - | $11.11 M(-79.6%) | $75.83 M(-33.2%) |
| Jun 2023 | - | $54.33 M(+1328.1%) | $113.59 M(+89.4%) |
| Mar 2023 | - | $3.80 M(-42.3%) | $59.98 M(+10.4%) |
| Dec 2022 | $54.33 M(+4.7%) | $6.59 M(-86.5%) | $54.33 M(+10.4%) |
| Sep 2022 | - | $48.87 M(+6677.7%) | $49.22 M(+3285.1%) |
| Jun 2022 | - | $721.00 K(-138.9%) | $1.45 M(-96.9%) |
| Mar 2022 | - | -$1.85 M(-224.7%) | $47.59 M(-8.3%) |
| Dec 2021 | $51.88 M(-76.8%) | $1.49 M(+35.1%) | $51.88 M(-7.2%) |
| Sep 2021 | - | $1.10 M(-97.7%) | $55.91 M(-5.1%) |
| Jun 2021 | - | $46.85 M(+1821.0%) | $58.89 M(-73.5%) |
| Mar 2021 | - | $2.44 M(-55.8%) | $222.46 M(-0.7%) |
| Dec 2020 | $223.95 M(+150.6%) | $5.51 M(+34.9%) | $223.95 M(+2.0%) |
| Sep 2020 | - | $4.09 M(-98.1%) | $219.63 M(+0.2%) |
| Jun 2020 | - | $210.42 M(+5263.8%) | $219.23 M(+1755.3%) |
| Mar 2020 | - | $3.92 M(+226.9%) | $11.82 M(-86.8%) |
| Dec 2019 | $89.37 M | $1.20 M(-67.4%) | $89.37 M(-1.5%) |
| Sep 2019 | - | $3.68 M(+22.4%) | $90.76 M(+3.0%) |
| Jun 2019 | - | $3.01 M(-96.3%) | $88.14 M(-52.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | $81.48 M(+3042.2%) | $185.02 M(+75.5%) |
| Dec 2018 | $105.42 M(-49.0%) | $2.59 M(+145.1%) | $105.42 M(-3.9%) |
| Sep 2018 | - | $1.06 M(-98.9%) | $109.72 M(-40.3%) |
| Jun 2018 | - | $99.89 M(+5219.1%) | $183.74 M(+119.6%) |
| Mar 2018 | - | $1.88 M(-72.8%) | $83.67 M(-59.5%) |
| Dec 2017 | $206.79 M(-8.6%) | $6.89 M(-90.8%) | $206.79 M(-19.2%) |
| Sep 2017 | - | $75.08 M(<-9900.0%) | $255.89 M(+40.6%) |
| Jun 2017 | - | -$184.00 K(-100.1%) | $182.07 M(-27.6%) |
| Mar 2017 | - | $125.00 M(+123.2%) | $251.33 M(+11.1%) |
| Dec 2016 | $226.18 M(+84.4%) | $56.00 M(+4365.6%) | $226.18 M(+32.6%) |
| Sep 2016 | - | $1.25 M(-98.2%) | $170.51 M(-5.1%) |
| Jun 2016 | - | $69.08 M(-30.8%) | $179.72 M(-19.5%) |
| Mar 2016 | - | $99.84 M(>+9900.0%) | $223.26 M(+82.0%) |
| Dec 2015 | $122.69 M(-9.8%) | $330.00 K(-96.8%) | $122.69 M(-40.5%) |
| Sep 2015 | - | $10.46 M(-90.7%) | $206.13 M(+6.3%) |
| Jun 2015 | - | $112.63 M(<-9900.0%) | $193.88 M(+43.4%) |
| Mar 2015 | - | -$729.00 K(-100.9%) | $135.22 M(-0.5%) |
| Dec 2014 | $135.96 M(+1265.6%) | $83.77 M(-4795.4%) | $135.96 M(+160.5%) |
| Sep 2014 | - | -$1.78 M(-103.3%) | $52.19 M(-3.3%) |
| Jun 2014 | - | $53.97 M(>+9900.0%) | $53.97 M(>+9900.0%) |
| Mar 2014 | - | $8000.00 | $8000.00 |
| Dec 2013 | $9.96 M(-63.0%) | - | - |
| Dec 2012 | $26.94 M | - | - |
FAQ
- What is Coherus BioSciences annual cash flow from financing activities?
- What is the all time high annual CFF for Coherus BioSciences?
- What is Coherus BioSciences annual CFF year-on-year change?
- What is Coherus BioSciences quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Coherus BioSciences?
- What is Coherus BioSciences quarterly CFF year-on-year change?
- What is Coherus BioSciences TTM cash flow from financing activities?
- What is the all time high TTM CFF for Coherus BioSciences?
- What is Coherus BioSciences TTM CFF year-on-year change?
What is Coherus BioSciences annual cash flow from financing activities?
The current annual CFF of CHRS is $69.60 M
What is the all time high annual CFF for Coherus BioSciences?
Coherus BioSciences all-time high annual cash flow from financing activities is $226.18 M
What is Coherus BioSciences annual CFF year-on-year change?
Over the past year, CHRS annual cash flow from financing activities has changed by +$15.27 M (+28.12%)
What is Coherus BioSciences quarterly cash flow from financing activities?
The current quarterly CFF of CHRS is -$167.00 K
What is the all time high quarterly CFF for Coherus BioSciences?
Coherus BioSciences all-time high quarterly cash flow from financing activities is $210.42 M
What is Coherus BioSciences quarterly CFF year-on-year change?
Over the past year, CHRS quarterly cash flow from financing activities has changed by -$11.27 M (-101.50%)
What is Coherus BioSciences TTM cash flow from financing activities?
The current TTM CFF of CHRS is -$186.84 M
What is the all time high TTM CFF for Coherus BioSciences?
Coherus BioSciences all-time high TTM cash flow from financing activities is $255.89 M
What is Coherus BioSciences TTM CFF year-on-year change?
Over the past year, CHRS TTM cash flow from financing activities has changed by -$262.67 M (-346.40%)